ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) approved in the EU for people with CF 6 years and older with at least one non-class I mutation in the CFTR ...

VANCOUVER, Canada & DALLAS, TX, USA I July 02, 2025 I Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” , or the “Company”), a biopharmaceutical ...

JERSEY CITY, NJ, USA I July 02, 2025 I Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today announced that the Phase 2 ELENA ...

RAHWAY, NJ, USA I July 02, 2025 I Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...

CHELMSFORD, MA, USA & NOVI, MI, USA & DÜSSELDORF, Germany & TOKYO, Japan I July 02, 2025 I Asahi Kasei Pharma has started trial drug ...

BASEL, Switzerland I July 1, 2025 I Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced the start of ...

VIENNA, Austria I June 30, 2025 I invIOs GmbH (“invIOs”), a privately held biotechnology company focused on developing innovative cancer immunotherapies, ...

BASEL, Switzerland I July 02, 2025 I BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of ...

MOUNTAIN VIEW, CA, USA I July 01, 2025 I IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company that has focused on developing engineered IgM-based ...

Two oral presentations to highlight the safety, immunogenicity, and future development of AV-1959R for primary and secondary prevention of Alzheimer's disease ...

Abeona will receive a license payment and potential development, regulatory, and sales milestones, and royalties ...

UNP to receive a double digit million dollar upfront payment, near-term payments and up to approximately $1.5B in potential milestone payments plus ...